Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes.
We investigated the signal transduction pathway of IL-12 and showed that lisofylline (LSF) inhibited the signal transducer and activator of transcription factor-4 (STAT4) activation. Interruption of IL-12-mediated STAT4 activation prevented autoimmune diabetes in NOD mice.
Yang
Zandong
Z
University of Virginia, Charlottesville, Virginia 22908, USA. jln2n@virginia.edu
Chen
Meng
M
Fialkow
Lawrence B
LB
Ellett
Justin D
JD
Wu
Runpei
R
Nadler
Jerry L
JL
D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D018664:Interleukin-12 / Q000378:metabolism; D010431:Pentoxifylline / Q000031:analogs & derivatives* / Q000494:pharmacology*; D010766:Phosphorylation; D050797:STAT4 Transcription Factor; D015398:Signal Transduction; D015534:Trans-Activators / Q000037:antagonists & inhibitors* / Q000378:metabolism
D004268:DNA-Binding Proteins; D007166:Immunosuppressive Agents; D050797:STAT4 Transcription Factor; C494090:STAT4 protein, human; D015534:Trans-Activators; D018664:Interleukin-12; C025189:lisofylline; D010431:Pentoxifylline